FEV<sub>1</sub>、IC对哮喘合并慢性阻塞性肺疾病的诊断价值

doi:10.3969/j.issn.1671-7171.2025.07.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1230 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the diagnostic value of forced expiratory volume in 1 second (FEV₁) and inspiratory capacity (IC) in asthma-COPD overlap (ACO). 【Methods】A total of 47 patients with chronic obstructive pulmonary disease (COPD,the control group) and 52 patients with ACO (the observation group) admitted to our hospital from February 2020 to February 2025 were selected. FEV₁ and IC were detected in both groups. Patients were graded according to lung function. Spearman correlation coefficient was used to analyze the correlation between FEV₁, IC and lung function grading. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of FEV₁ combined with IC for ACO. 【Results】FEV₁ and IC in the observation group were lower than those in the control group (P<0.05); FEV₁ and IC in patients with grade Ⅳ were lower than those in patients with grade Ⅰ, Ⅱ and Ⅲ (P<0.05). Correlation analysis showed that FEV₁ and IC were negatively correlated with lung function grading (P<0.05). ROC analysis results showed that the sensitivity and specificity of FEV₁ combined with IC in diagnosing ACO patients were 84.6% and 72.3% respectively, and the area under the ROC curve was 0.806, which were better than those of single index detection. 【Conclusion】FEV₁ and IC are significantly decreased in patients with ACO, and are negatively correlated with lung function grading. The combined detection of FEV₁ and IC has certain diagnostic value for ACO, with good clinical application prospects.

Key words： Pulmonary Disease, Chronic Obstructive Asthma Forced Expiratory Volume

Received: 27 April 2025

PACS:

R563

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yuan
	MA Ning

Cite this article:

LIU Yuan,MA Ning. Diagnostic Value of FEV₁ and IC in Asthma-COPD Overlap[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(7): 1116-1118.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.07.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I7/1116

[1] 吉瑞瑞,肖莹,赵云云. 经鼻高流量湿化氧疗与常规鼻导管吸氧治疗在COPD中的疗效比较[J].吉林医学,2025,46(3):584-587.
[2] 赵文翰,禤美玲,李庚,等. 倡议应用临床数据交换标准协会的治疗领域标准提高中医药治疗COPD的临床试验效率[J].中药新药与临床药理,2024,35(8):1255-1263.
[3] 刘丽琼. 噻托溴铵联合布地奈德福莫特罗治疗哮喘-慢阻肺重叠综合征的临床疗效[J].临床合理用药杂志,2021,14(30):109.
[4] 卢志萍,吴生坚. 沙丁胺醇联合布地奈德治疗哮喘:COPD重叠综合征的临床疗效[J].临床合理用药,2023,16(9):74-76.
[5] 焦静文,钱前,王勇生,等. 联合ADL、FEV₁％pred、HCT对COPD急性加重患者并发Ⅱ型呼吸衰竭的预测价值研究[J].临床肺科杂志,2023,28(6):905-909.
[6] 曹杉, 赖雁平, 李彬. 呼出气一氧化氮在支气管哮喘-慢性阻塞性肺疾病重叠诊治中的应用价值[J].中国现代医学杂志, 2020, 30(6):95-99.
[7] 世界中医药学会联合会. 国际中医临床实践指南 COPD[J].世界中医药,2020,15(7):1084-1092.
[8] 孙永昌. ACO综合征指南解读[J].中国呼吸与危重监护杂志,2014,13(4):325-329.
[9] 高晓雪,李艳斐,刘保珠. 西医常规治疗对COPD急性加重期患者治疗疗效影响因素分析[J].中国药师,2024,27(7):1248.
[10] 杨旖,李群,贺孟君,等. C反应蛋白等与急性加重期COPD合并Ⅱ型呼吸衰竭患者无创通气治疗的关系[J].河北医学,2023,29(9):1559-1564.
[11] 冼美兰,黄奕荣,郑少端,等. FEV₁/FEV6和FEV3/FVC联合筛查对COPD早期诊断及预后判断的价值[J].中国医学创新,2021,18(4):144-147.
[12] 郑忠生, 蔡举瑜, 叶铭植,等. 呼出气一氧化氮测定在哮喘-慢性阻塞性肺疾病重叠综合征诊疗中的应用[J].广东医学,2019,40(1):145-147.
[13] 程梦真, 顾宇彤, 宋元林. 支气管哮喘-慢性阻塞性肺疾病重叠的治疗现状[J].中华结核和呼吸杂志, 2019, 42(12):958-960.
[14] 孙行行,吴文汇,刘锦铭. 深吸气量在COPD患者中的临床应用价值[J].国际呼吸杂志,2019,39(5):387-390.
[15] 王芳, 姜晨宇, 罗旭平, 等. 深吸气量在鉴别慢性阻塞性肺疾病和支气管哮喘-慢性阻塞性肺疾病重叠中的应用价值研究[J].中国全科医学, 2019,22(33):4053-4057.
[16] 伍灿,杨娟,谢婧军. IC及FEV₁在COPD和ACO鉴别诊断中的应用价值[J].检验医学与临床,2022,19(8):1018-1021.
[17] 陈敏,王晓霞,陈锋. 深吸气量及肺总量对COPD再次急性加重的预测价值[J].中国呼吸与危重监护杂志,2021,20(10):690-693.